Cogent Biosciences (NASDAQ:COGT) Stock Price Down 10.2% – Should You Sell?

Cogent Biosciences, Inc. (NASDAQ:COGT) shares fell 10.2% on Wednesday . The company traded as low as $34.40 and last traded at $34.5740. 1,131,754 shares were traded during mid-day trading, a decline of 45% from the average session volume of 2,062,567 shares. The stock had previously closed at $38.49.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Cogent Biosciences to $67.00 and gave the stock an “overweight” rating in a research report on Friday, December 19th. UBS Group raised shares of Cogent Biosciences to a “strong-buy” rating in a research report on Wednesday, January 7th. Robert W. Baird set a $35.00 target price on shares of Cogent Biosciences in a research note on Thursday, February 19th. Wall Street Zen downgraded shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, Jefferies Financial Group began coverage on shares of Cogent Biosciences in a research note on Monday, March 16th. They issued a “buy” rating and a $55.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.45.

Cogent Biosciences Trading Down 8.9%

The company has a debt-to-equity ratio of 0.41, a quick ratio of 14.23 and a current ratio of 14.23. The business has a fifty day simple moving average of $37.04 and a 200 day simple moving average of $30.98. The stock has a market capitalization of $5.69 billion, a price-to-earnings ratio of -16.23 and a beta of 0.47.

Cogent Biosciences (NASDAQ:COGT) last posted its earnings results on Tuesday, February 17th. The technology company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, research analysts expect that Cogent Biosciences, Inc. will post -2.42 EPS for the current year.

Insider Transactions at Cogent Biosciences

In other Cogent Biosciences news, Director Fairmount Funds Management Llc sold 3,500,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $36.40, for a total transaction of $127,400,000.00. Following the transaction, the director owned 5,503,418 shares in the company, valued at $200,324,415.20. This represents a 38.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.29% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cogent Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Voya Investment Management LLC grew its holdings in shares of Cogent Biosciences by 110.0% during the 3rd quarter. Voya Investment Management LLC now owns 61,623 shares of the technology company’s stock worth $885,000 after purchasing an additional 32,279 shares in the last quarter. Federated Hermes Inc. raised its stake in Cogent Biosciences by 4,661,150.0% in the third quarter. Federated Hermes Inc. now owns 93,225 shares of the technology company’s stock valued at $1,339,000 after purchasing an additional 93,223 shares in the last quarter. Fairmount Funds Management LLC lifted its position in Cogent Biosciences by 44.6% during the third quarter. Fairmount Funds Management LLC now owns 9,003,418 shares of the technology company’s stock worth $129,289,000 after purchasing an additional 2,777,777 shares during the period. Vanguard Group Inc. lifted its position in Cogent Biosciences by 18.9% during the third quarter. Vanguard Group Inc. now owns 7,757,662 shares of the technology company’s stock worth $111,400,000 after purchasing an additional 1,234,711 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in Cogent Biosciences during the third quarter worth about $885,000.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.